Navigation Links
Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
Date:5/7/2012

LA JOLLA, Calif., May 7, 2012 /PRNewswire/ -- Zenobia Therapeutics, Inc. (Zenobia), the leader in fragment-based lead discovery (FBLD) for CNS diseases and FBLD/structural biology services, and BioBlocks, Inc. (BioBlocks), a leader in medicinal chemistry services and novel building block products, announced today that they are adding a 284 compound fragment library to their product offerings.  The library, ZB-Fragment Library 2, is ready for screening by all popular methods, contains soluble, verified protein binders, is shape and functionally diverse, and has an average molecular weight of 161.4 Da. The library was constructed by combining BioBlocks' unique expertise in medicinal chemistry and scaffold design with Zenobia's expertise in FBLD. Vicki Nienaber, Ph.D., President, CSO and founder of Zenobia, reported the first fragment-based crystallographic screening method (Nature Biotechnology 2000) and Robert Meadows, Ph.D. co-founder of Zenobia is an inventor of the SARbyNMR method (Science 1996). Industry veteran BioBlocks medicinal chemists have advanced numerous leads into preclinical and clinical development and have created a lead discovery platform capable of generating high quality patentable leads in a cost and time efficient manner.    

"Our customers have experienced an impressive success-rate in identifying valuable hits with Zenobia Fragment Library 1 with many returning to purchase additional copies. Establishing a collaborative relationship with BioBlocks allows us to jointly provide Fragment Library 2 with added core diversity and medicinal chemistry readiness using BioBlocks' unique expertise in creating leads from its building blocks," said Dr. Nienaber.  BioBlocks CEO, Dr. Pallai, said, "BioBlocks' core strength is the medicinal chemistry we utilize in collaborative drug discovery programs with our clients. Working with Zenobia allows us to take advantage of their unparalleled capabilities and experience in FBDD and SBDD and combine it with our expertise in fast fragment evolution, lead identification and optimizing compounds for pharmaceutical use. Our collaborative Fragment Library 2 provides a high quality starting point to generate lead compounds. With optimization, the final compounds are significantly more likely to occupy the high probability region of drug space than those developed from a typical HTS hit."   

Like Library 1, Library 2 is a small, cherry picked selection of diverse chemotypes and shapes, selected for manageable flexibility and compact interactions with target sites. Fragment functional groups are selected for their medicinal chemistry readiness and pharmaceutical appeal. There is no overlap between Library 1 and Library 2 so screening both will provide a wider variety of initial hits. The compounds are all soluble (200mM in DMSO), so screening with different methods is straightforward.

Through consulting or collaborations, Zenobia and BioBlocks offer structural biology, FBLD and medicinal chemistry expertise in advancing SAR around fragment hits.  

About Zenobia

Zenobia provides a commercial fragment library, and access to their structural biology, crystallography and fragment-based lead discovery expertise through partnerships, consulting and collaborations. Zenobia's internal programs combine fragment-based lead discovery with the expertise of biologists and clinicians to find treatments for devastating illnesses for which there is no disease altering treatment such as Parkinson's and Huntington's disease.

About BioBlocks

BioBlocks provides medicinal chemistry expertise to clients in the drug discovery community. In our collaborative projects we optimize partner's hits to leads and preclinical candidates. Our Leap-to-Lead platform addresses fundamental issues in drug discovery – the high attrition rate and lack of novelty found in typical HTS hits - by providing an alternative source for high quality tractable leads with multiple possible optimization pathways.  

For additional information on BioBlocks, Inc., contact Dr. Peter Pallai at ppallai@bioblocks.com or visit www.bioblocks.com. For additional information on Library 2 please contact fragments@bioblocks.com or Zenobia, please see below.

For additional information on Zenobia Therapeutics, Inc., contact Dr. Vicki Nienaber at vicki@zenobiatherapeutics.com or visit www.zenobiatherapeutics.com. For additional information on Zenobia's Fragment Library 1 or 2, contact Erika Zehm at erika@zenobiatherapeutics.com.


'/>"/>
SOURCE Zenobia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Cell Therapeutics, Inc. (CTI) to Host Conference Call April 19, 8:30 AM ET
3. Nile Therapeutics, Inc. Completes $1.34 Million Registered Direct Offering
4. Nile Therapeutics, Inc. to Raise $1.4 Million in Registered Direct Offering
5. Echo Therapeutics, Inc. Announces 2011 Financial Results
6. Cell Therapeutics, Inc. (CTI) Reports Fourth Quarter and Year-End Financial Results and Milestones
7. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2011 Financial Results on March 7
8. Stemline Therapeutics, Inc. Names Eric K. Rowinsky, M.D. Chief Medical Officer and Head of Research and Development
9. Cell Therapeutics, Inc. Announces Institutional Investors Purchase $20 Million of Preferred Stock and Warrants
10. Cell Therapeutics, Inc. (CTI) to Present at 10th Annual BIO Investor Forum
11. Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)... N.Y. , May 5, 2017  Hill-Rom Holdings, ... will add approximately 100,000 square feet to its Welch ... September 2016 its commitment to bring more than 100 ... , where Welch Allyn has maintained a significant presence ... help accommodate these new positions, a large portion of ...
(Date:5/4/2017)... CAESAREA, Israel , May 4, 2017  DarioHealth ... with mobile health and big data solutions, today announced ... an A&D Company, and STI Technologies Limited to lower ... effective immediately. Through STI,s innoviCares card, which is available ... , DarioHealth customers will be eligible for additional ...
(Date:5/3/2017)... 3, 2017  Getinge, a leading global provider ... enhancement and cost efficiency within healthcare and life ... contemporary practice demonstrating that intra-aortic balloon counterpulsation (IABC) ... ill patients. The single-center, retrospective, observational study showed ... MEGA ® 50cc intra-aortic balloon (IAB) in ...
Breaking Medicine Technology:
(Date:5/26/2017)... York, NY (PRWEB) , ... May 26, 2017 , ... ... Health & Wound Care" campaign in USA Today, which will educate readers on how ... side of the campaign, a large focus is placed on melanoma. Dancing with the ...
(Date:5/26/2017)... , ... May 26, 2017 , ... Amir Qureshi, MD ... a powerfully versatile, patient-centric spinal cord stimulation system. The Nuvectra™ Algovita SCS System has ... are pleased to be the first in Arkansas to introduce the most powerful SCS ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... ... the first ever copper, antimicrobial, mesh back 24/7 task chair specifically designed for ... applications. “We are thrilled to partner with Cupron® to provide customers with ...
(Date:5/26/2017)... Illinois (PRWEB) , ... May 26, 2017 , ... Silver ... The community, which is located on more than four acres of land at 5620 ... independence. , The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each ...
(Date:5/26/2017)... ... ... “THE FLINTHILLS FAMILY-Our Journey to the Cross”: the personal journey of Bob Massey and his ... of published authors, Bob and Margaret Massey. Bob Massey is small in stature but ... leather tough." His love for others is apparent in all of his life decisions. ...
Breaking Medicine News(10 mins):